The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 20, 2024
Filed:
Apr. 22, 2022
Bayer Aktiengesellschaft, Leverkusen, DE;
Sandra Berndt, Hohen Neuendorf, DE;
Christian Bertling, Wuppertal, DE;
Pascale Buchmann, Leverkusen, DE;
Philipp Ellinger, Düsseldorf, DE;
Katharina Filarsky, Düsseldorf, DE;
Matyas Gorjanacz, Berlin, DE;
Sabine Hoff, Potsdam, DE;
Nikolaus Pawlowski, Cologne, DE;
Helge Roider, Hohen Neuendorf, DE;
Beatrix Stelte-Ludwig, Wülfrath, DE;
Mark Trautwein, Wülfrath, DE;
Ernst Weber, Langenfeld, DE;
Uwe Gritzan, Leverkusen, DE;
Oliver von Ahsen, Berlin, DE;
Christian Votsmeier, Cologne, DE;
Wiebke Maria Nadler, Langenfeld, DE;
Patrick Jones, Oakland, CA (US);
Pedro Paz, Hercules, CA (US);
Su-Yi Tseng, San Francisco, CA (US);
Phaik Lyn Oh, Emeryville, CA (US);
Bayer Aktiengesellschaft, Leverkusen, DE;
Abstract
The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human,and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.